New neuroscience reported by ScienceDaily suggests psychedelics may produce hallucinations by reducing real-time visual input and increasing memory-driven perception. Psychedelic compounds act strongly at the serotonin 5-HT2A receptor, which can dampen activity in brain regions that process incoming visual information. When external signals are turned down, the brain appears to “fill in” experience with internally stored material—like memory fragments.

OpenAI retired GPT-4o on Feb 13, 2026 (right before Valentine’s Day), and The Guardian reports that many users reacted with real grief and anger because they’d come to use the chatbot for companionship and emotional support. The article describes how GPT-4o’s “warm,” relationship-like tone helped some users feel seen—especially people who reported loneliness or mental health challenges—and how its removal felt like a sudden rupture with no closure.

(February 19, 2026) Recent wastewater analysis in Nantucket, Massachusetts has revealed cocaine concentrations up to three times the U.S. national average, underscoring the potential of wastewater surveillance as a tool for tracking community drug trends. Testing conducted since summer 2025 at the town’s Surfside treatment facility found peak cocaine readings of nearly 2,950 nanograms per liter, significantly higher than typical national wastewater benchmarks of around 900–1,000 ng/L.

(February 20, 2026) The U.S. Department of Health and Human Services’ Administration for Children and Families (ACF) has announced that three FDA-approved Medications for Opioid Use Disorder (MOUD) — buprenorphine, methadone, and naltrexone — are now eligible for funding under Title IV-E Prevention Services.

Mertz Taggart’s Q4 2025 Behavioral Health M&A Report describes a market that stayed active but became far more selective. The firm counted 180 total behavioral health transactions in 2025, slightly up from 176 in 2024, with ~39 deals in Q4 (about 30 M&A and 9 growth deals). The report says deal timelines lengthened as lenders conducted “forensic” diligence on insurance receivables and cash collections—an effect lingering from the Change Healthcare disruption and ongoing Medicaid uncertainty.

New research from King’s College London indicates that deaths from nitazenes—a class of extremely potent synthetic opioids—are likely being significantly undercounted in the UK, with implications for public health surveillance and intervention design. Nitazenes can be up to 500 times stronger than heroin, and while the UK National Crime Agency (NCA) reported 333 nitazene-linked fatalities in 2024, scientists now suggest the true figure may be about one-third higher because many deaths go undetected in standard postmortem toxicology.

A Washington Post/Dr. Leana Wen newsletter highlights a growing trend of psychedelic microdosing in the U.S., with an estimated 10 million adults reportedly microdosing substances such as psilocybin, MDMA, and LSD, often to self‑treat depression, anxiety, or enhance focus. However, experts caution that microdosing lacks standardized definitions, oversight, or safety data, and unregulated products may contain unknown or unsafe compounds.

In recent months, communities in Upstate New York have seen a worrisome rise in nonfatal overdoses linked to synthetic cannabis — commonly known as “K2” or “spice” — even as broader opioid-related fatalities continue to decline. Law enforcement and public health officials in the Capital Region report that, after several years of decreasing overdose trends, emergency departments and first responders are now encountering K2 as an increasing contributor to overdose events.

The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) announced a civil enforcement program to implement and enforce federal confidentiality protections for substance use disorder patient records under 42 CFR Part 2. The initiative, tied to the Great American Recovery Initiative, brings civil penalties for non‑compliance with privacy rules, aligning Part 2 protections more closely with HIPAA standards.

Artificial intelligence is already reshaping marketing, but a new evolution known as agentic AI is pushing the industry into its next phase.